Navigation Links
Boston Scientific Schedule Of Major Presentations At The American College Of Cardiology 2013
Date:3/4/2013

NATICK, Mass., March 4, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of Cardiology which takes place March 9-11 in San Francisco, California. The clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Schedule of Events
All programs are Pacific Standard Time with events held at the Moscone Center.

Saturday, March 9

  • PREVAIL Late Breaking Clinical Trial Results: David R. Holmes Jr. , M.D., Mayo Clinic, Rochester, Minn., will present the acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN® left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. PREVAIL is a confirmatory trial on the safety and efficacy of the WATCHMAN device. Results will be presented at 9:10 a.m. in South, Esplanade Ballroom.
  • PLATINUM Vessel Straightening Analysis: Jeffrey J. Popma , M.D., Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass., will present the results of the PLATINUM vessel straightening analysis, designed to evaluate the impact of stent design on native vessel distortion following coronary artery stenting in severely angulated lesions.  Results will be presented at 10:00 a.m. in the Poster Session area, Expo North.

Sunday, March 10

  • PLATINUM Three-Year Clinical Trial Results:  Ian T. Meredith , M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present the three-year data of the PLATINUM Workhorse clinical trial. Two year follow-up of this trial confirmed the safety and efficacy of the platinum chromium PROMUS Element™ Plus Stent System, which uses the combination of the market-leading everolimus drug and fluorinated copolymer. Results will be presented at 8:15 a.m. in West, Room 2001.

Monday, March 11

  • REPRISE I Feasibility Study:  Ian T. Meredith, M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present six-month study results of the differentiated second generation Lotus Aortic Valve Replacement System.  REPRISE I was designed as a feasibility study with a primary endpoint of clinical procedural success. Results will be presented at 9:15 a.m. in West, Room 2009.   

Conference attendees are invited to visit Boston Scientific and "Technologies that transform tomorrow and Products that perform today" at booth N5933.

The WATCHMAN and Lotus devices are investigational devices and not available for sale in the United States.

All clinical data results are embargoed until the time of each scientific presentation.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials and impact of their results, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:  

Steven Campanini
508-652-5740 (office)
Global Media Relations
Boston Scientific Corporation
media@bsci.com

Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
6. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
9. Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators
10. Boston Scientific Closes Cameron Health Acquisition
11. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
(Date:6/9/2017)... and INDIANAPOLIS , June ... are living with diabetes. In a further effort to ... people affected by this condition, the International Diabetes Federation ... LLY ) have come together for the second phase ... and Systems programme (BRIDGES 2), reaffirming their commitment to ...
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... American Farmer proudly ... episode of the award winning television series, scheduled to broadcast fourth quarter 2017. American ... originated as a regional supplier of garden pea seed. As demand grew, the small ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom ... technical specifications . , 2017 has seen an explosion of token launches by ... offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, ...
(Date:6/27/2017)... ... 2017 , ... A January 18th article on medGadget reports that ... by the year 2024 according to a new report. The article also notes that ... titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that ...
(Date:6/27/2017)... London, CT (PRWEB) , ... June 27, 2017 ... ... the Alice P. Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering ... Toback and Urbanski offered their experience in these popular periodontal procedures. Drs. Toback ...
Breaking Medicine News(10 mins):